Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts

scientific article published on September 1998

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/2012
P698PubMed publication ID9734395
P5875ResearchGate publication ID13552195

P2093author name stringLu Y
Schmidt AM
Stern D
Lee KJ
Chow WS
Park L
Ferran LJ Jr
Raman KG
P2860cites workApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial treeQ72689998
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research GroupQ27861088
Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cellsQ28509783
THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUMQ29391553
Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein EQ29615236
Advanced glycosylation end products in tissue and the biochemical basis of diabetic complicationsQ34049428
The role of lipid peroxidation and antioxidants in oxidative modification of LDL.Q35379559
Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complicationsQ35661794
Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteinsQ35748423
Glucose and diabetic vascular disease.Q36379991
Quantitative assessment of atherosclerotic lesions in miceQ36456167
Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins.Q37308593
Increased atherosclerosis in streptozotocin-induced diabetic miceQ37353969
Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diaQ38292287
Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic ratsQ39759463
The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amylQ39770000
Streptozotocin-Induced Pancreatic Insulitis: New Model of Diabetes MellitusQ39998473
The role of oxidized lipoproteins in atherogenesisQ41043422
Diabetes and cardiovascular disease. The Framingham studyQ41509493
Effect of the Antioxidant N,N′ -Diphenyl 1,4-Phenylenediamine (DPPD) on Atherosclerosis in ApoE-Deficient MiceQ41671565
Is hyperglycemia associated with cardiovascular disease? The Framingham StudyQ41762879
Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbitsQ45252141
Activation of the Receptor for Advanced Glycation End Products Triggers a p21 -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant StressQ50180621
5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects.Q51615365
Metabolic control in 131 juvenile-onset diabetic patients as measured by HbA1c: relation to age, duration, C-peptide, insulin dose, and one or two insulin injections.Q51650530
A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infectionQ59068486
The dark side of glucoseQ71563592
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectatherosclerosisQ12252367
P304page(s)1025-1031
P577publication date1998-09-01
P1433published inNature MedicineQ1633234
P1476titleSuppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
P478volume4

Reverse relations

cites work (P2860)
Q387591942016 ATVB Plenary Lecture: Receptor for Advanced Glycation Endproducts and Implications for the Pathogenesis an Treatment of Cardiometabolic Disorders: Spotlight on the Macrophage
Q91960865A Receptor of the Immunoglobulin Superfamily Regulates Adaptive Thermogenesis
Q38271792A new glycation product 'norpronyl-lysine,' and direct characterization of cross linking and other glycation adducts: NMR of model compounds and collagen
Q28507626A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis
Q48103881ADAM10 modulates calcitriol-regulated RAGE in cardiomyocytes
Q51747235AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease.
Q36844673AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice
Q52790388AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis.
Q38213275AGEs and chronic subclinical inflammation in diabetes: disorders of immune system
Q38116590AGEs, contributors to placental bed vascular changes leading to preeclampsia
Q46734928AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat.
Q43710091Activation of MAPK by modified low-density lipoproteins in vascular smooth muscle cells
Q39883888Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice
Q35086500Activation of the receptor for advanced glycation end products induces nuclear inhibitor of protein phosphatase-1 suppression
Q59703917Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knock-out mice
Q93355257Advanced Glycation End Products Stimulate Angiotensinogen Production in Renal Proximal Tubular Cells
Q26774333Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS?
Q35796793Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease
Q41682122Advanced glycation end products (AGEs) activate mast cells
Q40789629Advanced glycation end products (AGEs)-induced expression of TGF-beta 1 is suppressed by a protease in the tubule cell line LLC-PK1.
Q37433970Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis
Q36069797Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation
Q34579585Advanced glycation end products and vascular structure and function
Q34542291Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption
Q30445160Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway
Q44947212Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression
Q36974285Advanced glycation end products, diabetes and ageing.
Q37780646Advanced glycation end products, oxidative stress and diabetic nephropathy
Q38081119Advanced glycation end products: role in pathology of diabetic cardiomyopathy
Q35672476Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease
Q37801314Advanced glycation endproducts: from precursors to RAGE: round and round we go.
Q35409645Age-related vascular stiffening: causes and consequences.
Q36099419Agents in development for the treatment of diabetic nephropathy
Q35133201Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE).
Q35090344Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats.
Q36543639Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice
Q38863647Altered Expression of NF- κ B and SP1 after Exposure to Advanced Glycation End-Products and Effects of Neurotrophic Factors in AGEs Exposed Rat Retinas.
Q37233185Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene
Q37609701An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients
Q38001410An update on advanced glycation endproducts and atherosclerosis
Q40021400Analysis and biological relevance of advanced glycation end-products of DNA in eukaryotic cells
Q46103013Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.
Q26822630Animal models of diabetic macrovascular complications: key players in the development of new therapeutic approaches
Q34067128Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm
Q34355358Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes
Q41886031Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond.
Q41202872Arterial calcification is driven by RAGE in Enpp1-/- mice
Q41504461Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis
Q37235902Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.
Q80253430Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes
Q35152739Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study
Q34949171Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS)
Q34107554Atherosclerosis and diabetes: the RAGE connection
Q28303607Atherosclerosis and restenosis: is there a role for RAGE?
Q36909193Atherosclerosis and the Hypercholesterolemic AGE-RAGE Axis
Q36857541Atherosclerosis in diabetes and insulin resistance
Q34269548Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats
Q40802125Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?
Q39199900Beneficial Effect of Glucose Control on Atherosclerosis Progression in Diabetic ApoE(-/-) Mice: Shown by Rage Directed Imaging.
Q29012485Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy
Q28131781Biochemistry and molecular cell biology of diabetic complications
Q54967677Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice.
Q34432623Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice
Q41893958Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice.
Q35825346Bone fragility in type 2 diabetes mellitus
Q35135006Bone marrow-derived mesenchymal stem cells improve the functioning of neurotrophic factors in a mouse model of diabetic neuropathy
Q37056305Bone metabolism and fracture risk in type 2 diabetes mellitus
Q38502595Cell Interactions with Vascular Regenerative MAA-Based Materials in the Context of Wound Healing
Q43257049Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosis
Q33971339Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide
Q38831558Cellular mechanisms and consequences of glycation in atherosclerosis and obesity
Q34890522Central role of RAGE-dependent neointimal expansion in arterial restenosis
Q24310573Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15
Q35882416Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products
Q42067799Ciprofloxacin inhibits advanced glycation end products-induced adhesion molecule expression on human monocytes
Q51742202Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
Q54764181Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels.
Q47948668Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes
Q58947783Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease
Q54941926Clinical and Biological Predictors of Plasma Levels of Soluble RAGE in Critically Ill Patients: Secondary Analysis of a Prospective Multicenter Observational Study.
Q34048575Clinical features of schizophrenia with enhanced carbonyl stress.
Q37875591Clinical science review article: understanding the implications of diabetes on the vascular system
Q44037770Cloning and characterization of soluble decoy receptors
Q35787903Cloning and expression of the rat nephrin homolog.
Q24292698Contribution of p16INK4a and p21CIP1 pathways to induction of premature senescence of human endothelial cells: permissive role of p53
Q33609776Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications
Q28168105Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins
Q34427072Coronary microvascular dysfunction in diabetes mellitus: A review
Q36938546Cross-susceptibility between periodontal disease and type 2 diabetes mellitus: an immunobiological perspective.
Q26781156Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management
Q33786872DJC Suppresses Advanced Glycation End Products-Induced JAK-STAT Signaling and ROS in Mesangial Cells
Q57549422Decreased plasma sRAGE levels in COPD: influence of oxygen therapy
Q50227375Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice
Q37202057Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice
Q34024334Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse
Q51550442Detection of Circulating Auto-Antibodies Against Ribosylated-LDL in Diabetes Patients.
Q28344139Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
Q91754413Diabetes Mellitus and Cardiovascular Disease
Q37333371Diabetes and atherosclerosis: is there a role for hyperglycemia?
Q37486465Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions
Q36744061Diabetes reduces aortic endothelial gap junctions in ApoE-deficient mice: simvastatin exacerbates the reduction
Q53486855Diabetes with poor glycaemic control does not promote atherosclerosis in genetically modified hypercholesterolaemic minipigs.
Q34470314Diabetes.
Q45072634Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Q30433016Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation
Q42031332Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha
Q36199128Diabetic vascular disease and the potential role of macrophage glucose metabolism
Q34733351Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF.
Q36963380Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
Q44474816Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice
Q35895741Differential activation of RAGE by HMGB1 modulates neutrophil-associated NADPH oxidase activity and bacterial killing
Q34399952Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice
Q64259519Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM
Q39158946Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?
Q37941867Do statins have a role in reduction/prevention of post-PCI restenosis?
Q64958363Dynamic fluctuations of advanced glycation end products and its C-terminal truncated receptor level in patients with acute ST-segment elevation myocardial infarction and undergoing diabetes or not: A retrospective study.
Q37578319Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease
Q34362687Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients
Q56905400Effects of Averrhoa bilimbi leaf extract on blood glucose and lipids in streptozotocin-diabetic rats
Q45241682Effects of diabetes and CETP expression on diet-induced atherosclerosis in LDL receptor-deficient mice.
Q64110582Efficacy of Co-administration of Liuwei Dihuang Pills and Ginkgo Biloba Tablets on Albuminuria in Type 2 Diabetes: A 24-Month, Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial
Q53595048Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.
Q36207823Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway.
Q42176457Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases.
Q42406006Endothelial dysfunction and vascular inflammation in type 2 diabetes: interaction of AGE/RAGE and TNF-alpha signaling
Q34747124Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation
Q37216724Endothelium-specific GTP cyclohydrolase I overexpression accelerates refractory wound healing by suppressing oxidative stress in diabetes
Q92848013Epigenetics and vascular diseases
Q73668176Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays
Q43059409Expression of S100A12 (EN-RAGE) in cystic fibrosis
Q81810954Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs
Q30873486FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products.
Q42227340Fibronectin glycation increases IGF-I induced proliferation of human aortic smooth muscle cells.
Q37526511Flow patterns regulate hyperglycemia-induced subendothelial matrix remodeling during early atherogenesis
Q34994616Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.
Q38258947Galectin-3: an emerging all-out player in metabolic disorders and their complications
Q37607192GeneOptimizer program-assisted cDNA reengineering enhances sRAGE autologous expression in Chinese hamster ovary cells
Q34080318Genetic modifiers of atherosclerosis in mice
Q55043209Glycaemic control in type 2 diabetic patients with chronic kidney disease: the impacts on enzymatic antioxidants and soluble RAGE.
Q38062900Glycated proteome: from reaction to intervention
Q34006261Glycoxidation and lipoxidation in atherogenesis
Q38221639Glycoxidation of biological macromolecules: a critical approach to halt the menace of glycation.
Q95515700GnRH impairs diabetic wound healing through enhanced NETosis
Q38939435HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
Q33930928High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes
Q33592848Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study
Q24795988How hyperglycemia promotes atherosclerosis: molecular mechanisms
Q24530027Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice
Q57817035Hyperglycemia Aggravates Diet-Induced Coronary Artery Disease and Myocardial Infarction in SR-B1-Knockout/ApoE-Hypomorphic Mice
Q35830289Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes.
Q55355643Hyperglycemia does not affect tissue repair responses in shear stress-induced atherosclerotic plaques in ApoE-/- mice.
Q37711215Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis
Q28260396Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein
Q24682735Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation
Q33556567Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands
Q28360470Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model
Q37768423Hyperoxia sensing: from molecular mechanisms to significance in disease
Q36893819Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway
Q53218782IL-1β enhances vascular smooth muscle cell proliferation and migration via P2Y2 receptor-mediated RAGE expression and HMGB1 release.
Q37305013IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies
Q28590453Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression
Q42013140Imaging RAGE expression in atherosclerotic plaques in hyperlipidemic pigs
Q40979636Imaging receptor for advanced glycation end product expression in mouse model of hind limb ischemia
Q42628303Immune activation resulting from NKG2D/ligand interaction promotes atherosclerosis
Q37325024Immune and inflammatory mechanisms of atherosclerosis (*)
Q37261617Immune mechanisms in atherosclerosis, especially in diabetes type 2
Q48511733Impact of diabetes on gingival wound healing via oxidative stress
Q42672104Impact of hyperglycemia and acute pancreatitis on the receptor for advanced glycation endproducts
Q50223052Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes
Q24337632In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE)
Q35876768Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss
Q34364237Induction of RAGE shedding by activation of G protein-coupled receptors
Q34326241Inflammation in nonhealing diabetic wounds: the space-time continuum does matter
Q36001244Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells
Q27317653Inhibition of nuclear factor of activated T-cells (NFAT) suppresses accelerated atherosclerosis in diabetic mice
Q27011696Insulin resistance, hyperglycemia, and atherosclerosis
Q52544667Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model.
Q24323192Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42
Q46517192Interferon-gamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100b
Q43907504Intra-peritoneal sRAGE treatment induces alterations in cellular distribution of CD19(+), CD3 (+) and Mac-1 (+) cells in lymphoid organs and peritoneal cavity
Q30317651Intraoperative sRAGE kinetics. A new age-related outcome predictor of cardiac surgery
Q36082148Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications
Q51446086Investigations on the reactions of α-dicarbonyl compounds with amino acids and proteins during in vitro digestion of biscuits.
Q41789363Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy
Q46468830Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells
Q33918403Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice
Q26766350Large animal models of cardiovascular disease
Q33344161Large scale isolation and purification of soluble RAGE from lung tissue
Q77578272Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE)
Q35944988Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis
Q26795694Linking RAGE and Nox in diabetic micro- and macrovascular complications
Q57182351Linking diabetes and atherosclerosis
Q44517931Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy
Q42256397Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients
Q57825219Low maternal serum matrix metalloproteinase (MMP)-2 concentrations are associated with preterm labor and fetal inflammatory response
Q37437155Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes
Q36478250Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling
Q38586884MEMBRANE TYPE 1-MATRIX METALLOPROTEINASE (MT1-MMP) IDENTIFIED AS A MULTIFUNCTIONAL REGULATOR OF VASCULAR RESPONSES.
Q38172884Macrophage-mediated glucolipotoxicity via myeloid-related protein 8/toll-like receptor 4 signaling in diabetic nephropathy
Q37107174Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications
Q22306395Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness
Q57131309Mechanistic targeting of advanced glycation end-products in age-related diseases
Q37139800Mice deficient in PKCbeta and apolipoprotein E display decreased atherosclerosis
Q35837912Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT.
Q64057969Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging
Q28070313Molecular Imaging of Vulnerable Atherosclerotic Plaques in Animal Models
Q26782445Molecular Pathways Regulating Macrovascular Pathology and Vascular Smooth Muscle Cells Phenotype in Type 2 Diabetes
Q36139535Mouse Specific Cleavage-Resistant RAGE Splice Variant
Q36766171Mouse models for studies of cardiovascular complications of type 1 diabetes
Q59133666Multimodal imaging of the receptor for advanced glycation end-products with molecularly targeted nanoparticles
Q37564063Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications
Q64076770Myocardial Ischemia and Diabetes Mellitus: Role of Oxidative Stress in the Connection between Cardiac Metabolism and Coronary Blood Flow
Q44357475N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.
Q37036184N(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status.
Q36297295N-butanol extracts of Morinda citrifolia suppress advanced glycation end products (AGE)-induced inflammatory reactions in endothelial cells through its anti-oxidative properties
Q54682072NBRI17671, a new antitumor compound, produced by Acremonium sp. CR17671.
Q38227386NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links
Q43687605Non-obese diabetic (NOD) mice exhibit an increased cellular immune response to glycated-LDL but are resistant to high fat diet induced atherosclerosis
Q29616101Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Q37990618Novel pathways and therapies in experimental diabetic atherosclerosis
Q38359414Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury
Q30993051O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice
Q44640723Oleate, not ligands of the receptor for advanced glycation end-products, promotes proliferation of human arterial smooth muscle cells
Q80362512Oxidative stress and diabetic vascular complications
Q36204491Oxidative stress and stress signaling: menace of diabetic cardiomyopathy
Q36891939Oxidative stress, AGE, and atherosclerosis
Q43109146Oxidative stress-associated rise of hepatic protein glycation increases inflammatory liver injury in uncoupling protein-2 deficient mice
Q37397476PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice
Q28362804PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice
Q34766912Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis
Q37494520Pathogenesis and pathophysiology of accelerated atherosclerosis in the diabetic heart.
Q42812060Pathological roles of advanced glycation end product receptors SR-A and CD36.
Q36065338Pathophysiology and Medical Treatment of Carotid Artery Stenosis
Q34018425Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation
Q43911870Periodontal disease and diabetes mellitus: discussion, conclusions, and recommendations
Q59804720Periodontal regenerative effect of enamel matrix derivative in diabetes
Q30309168Pimagedine: a novel therapy for diabetic nephropathy
Q30253065Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis
Q37176678Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation.
Q33723012Plasma levels of the pro-inflammatory protein S100A12 (EN-RAGE) are associated with muscle and fat mass in hemodialysis patients: a cross-sectional study
Q38197360Possible role of methylglyoxal and glyoxalase in arthritis
Q74708419Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure
Q57825168Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) – intra- and inter-individual variability in chronic hemodialysis patients
Q36108353Preserved DNA Damage Checkpoint Pathway Protects against Complications in Long-Standing Type 1 Diabetes
Q28508886Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE)
Q47730385Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress
Q60732952RAGE Gene Polymorphisms in Patients with Multiple Sclerosis
Q35102969RAGE Signaling Significantly Impacts Tumorigenesis and Hepatic Tumor Growth in Murine Models of Colorectal Carcinoma
Q35740332RAGE Suppresses ABCG1-Mediated Macrophage Cholesterol Efflux in Diabetes
Q37455857RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?
Q44032299RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response
Q36320548RAGE and its ligands: a lasting memory in diabetic complications?
Q36756482RAGE and modulation of ischemic injury in the diabetic myocardium
Q36969021RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases
Q48536125RAGE binds preamyloid IAPP intermediates and mediates pancreatic β cell proteotoxicity.
Q37860348RAGE biology, atherosclerosis and diabetes
Q36635410RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice
Q42263637RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
Q41243867RAGE inhibition reduces acute lung injury in mice.
Q41853060RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB
Q22010236RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides
Q28482199RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation
Q46142346RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice
Q33559727RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways.
Q46775210RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model
Q52857005RAGE polymorphisms and the heritability of insulin resistance: the Leeds family study.
Q33646761RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice
Q33346824RAGE signaling in inflammation and arterial aging
Q49413376RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice
Q27025295RAGE: a new frontier in chronic airways disease
Q35854488RAGE: a novel target for drug intervention in diabetic vascular disease
Q51061874Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults.
Q47118560Raman spectroscopy imaging reveals interplay between atherosclerosis and medial calcification in the human aorta.
Q37181988Reactive immunization suppresses advanced glycation and mitigates diabetic nephropathy
Q37384331Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response
Q37972674Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications
Q90643374Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and Animal Models
Q37997993Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure
Q36842628Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes
Q40899986Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response
Q22010208Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways
Q21285070Receptor for advanced glycation end products and its involvement in inflammatory diseases
Q36203962Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis
Q30378823Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia.
Q41884655Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2
Q41926813Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis
Q37373486Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.
Q34586849Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes
Q43090705Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity
Q34188756Receptor for advanced glycation endproducts mediates pro-atherogenic responses to periodontal infection in vascular endothelial cells
Q35009768Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings
Q22254188Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
Q36605862Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome
Q37400729Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue
Q35494903Regulation of RAGE for attenuating progression of diabetic vascular complications
Q38782723Regulation of Receptor for Advanced Glycation End Products (RAGE) Ectodomain Shedding and Its Role in Cell Function.
Q44499434Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products
Q40541205Regulation of inducible nitric oxide synthase expression in advanced glycation end product-stimulated raw 264.7 cells: the role of heme oxygenase-1 and endogenous nitric oxide
Q34321457Regulation of ligands for the NKG2D activating receptor
Q38523267Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease
Q35610210Role of HMGB1 in cardiovascular diseases
Q35929112Role of advanced glycation end products in cardiovascular disease.
Q36416215Role of diabetes in atherosclerotic pathogenesis. What have we learned from animal models?
Q46555270Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury.
Q24318401S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells
Q36631781S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets
Q33984573S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance
Q37837904S100B protein in neurodegenerative disorders
Q52666460SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice.
Q47879810Secretogranin III: a diabetic retinopathy-selective angiogenic factor.
Q37300540Senescence-dependent impact of anti-RAGE antibody on endotoxemic liver failure
Q46126412Serum advanced glycation end products (AGEs) are associated with insulin resistance
Q35844102Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes
Q80478922Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects
Q37729101Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis
Q37740359Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes
Q37158807Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events
Q35077903Skin autofluorescence, a non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis
Q27319831Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice.
Q36091982Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study
Q40126438Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein
Q54605224Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease.
Q34094369Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging
Q26780488Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome
Q82511623Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictor of Restenosis Following Percutaneous Coronary Intervention
Q64912818Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes.
Q61845347Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation
Q39636114Soluble receptor for advanced glycation end products (sRAGE) is present at high concentrations in the lungs of children and varies with age and the pattern of lung inflammation.
Q51620241Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population.
Q36263332Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study
Q34774357Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study
Q33613288Soluble receptor for advanced glycation end-products and progression of airway disease
Q90859382Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness
Q48100352Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE.
Q38795678Solution structure of the soluble receptor for advanced glycation end products (sRAGE).
Q35086814Spontaneously diabetic Ins2(+/Akita):apoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis
Q27678167Stable RAGE-Heparan Sulfate Complexes Are Essential for Signal Transduction
Q39106836Statins stimulate the production of a soluble form of the receptor for advanced glycation end products
Q27665039Structural Basis for Ligand Recognition and Activation of RAGE
Q40668935Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system
Q46061259Synergistic vasculogenic effects of AMD3100 and stromal-cell-derived factor-1α in vasa nervorum of the sciatic nerve of mice with diabetic peripheral neuropathy
Q73653690Synthesis and reactivity of the monosaccharide esters of amino acids as models of teichoic acid fragment
Q34415503TP receptors and oxidative stress hand in hand from endothelial dysfunction to atherosclerosis
Q60923225Targeted nanoparticles for multimodal imaging of the receptor for advanced glycation end-products
Q37424029Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation
Q47094524The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases
Q37091107The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
Q36139994The Mouse-Specific Splice Variant mRAGE_v4 Encodes a Membrane-Bound RAGE That Is Resistant to Shedding and Does Not Contribute to the Production of Soluble RAGE.
Q37355646The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth
Q33822512The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature
Q37560012The Role of Immunogenicity in Cardiovascular Disease
Q41729219The association between the RAGE G82S polymorphism, sRAGE and chronic periodontitis in Taiwanese individuals with and without diabetes.
Q48359381The association of low muscle mass with soluble receptor for advanced glycation end products (sRAGE): The Korean Sarcopenic Obesity Study (KSOS).
Q33615012The attenuation of Moutan Cortex on oxidative stress for renal injury in AGEs-induced mesangial cell dysfunction and streptozotocin-induced diabetic nephropathy rats
Q36787569The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications
Q34100112The biology of the receptor for advanced glycation end products and its ligands
Q34271106The contribution of mitochondria to common disorders
Q38023062The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes.
Q42849056The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions
Q36857011The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units.
Q73788217The functions of circulatory polymorphonuclear leukocytes in diabetic patients with and without diabetic triopathy
Q28570659The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells
Q36461096The ligand/RAGE axis: lighting the fuse and igniting vascular stress
Q34387881The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
Q28830568The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease
Q41879957The next generation of RAGE modulators: implications for soluble RAGE therapies in vascular inflammation
Q42037633The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment
Q57718003The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood
Q59340735The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients
Q38025026The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome
Q40877248The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells
Q37412673The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease
Q35649410The role of advanced glycation end products in the development of atherosclerosis
Q37860412The role of receptor for advanced glycation endproducts (RAGE) in infection
Q37464743Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
Q48101313Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes
Q53258066Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing?
Q90366910Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis
Q33700652Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?
Q46495572Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients
Q36245387Understanding RAGE, the receptor for advanced glycation end products
Q38134924Unlocking the biology of RAGE in diabetic microvascular complications
Q80968903Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis
Q36514906Uremic Toxicity of Advanced Glycation End Products in CKD.
Q35903021Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis
Q30444108Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice
Q36537262Vascular complications of diabetes: mechanisms of injury and protective factors
Q37636453Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms
Q34498985Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model
Q39951404Why does diabetes increase atherosclerosis? I don't know!
Q83105602[Current concepts of diabetic atherogenesis]
Q30318169[Protein glycation as a pathological mechanism in diabetes].
Q36867450sRAGE and risk of diabetes, cardiovascular disease, and death
Q36070548sRAGE in diabetic and non-diabetic critically ill patients: effects of intensive insulin therapy
Q36900801sRAGE induces human monocyte survival and differentiation

Search more.